Alleviare India

  Retevmo 80 mg capsule is a medication that is used for the treatment of certain types of cancer. The active ingredient in Retevmo is selpercatinib, which belongs to a class of drugs known as kinase inhibitors. Dosage The recommended dosage of Retevmo 80 mg capsule varies depending on the patient’s weight, age, and overall health condition. The doctor will determine the appropriate dose for each patient based on these factors. Retevmo 80 mg capsule is usually taken orally twice a day with or without food. The capsule should be swallowed whole with a glass of water. Patients should not crush, chew, or open the capsule. Uses Retevmo 80 mg capsule is indicated for the treatment of advanced non-small cell lung cancer (NSCLC), thyroid cancer, and other solid tumors that have a specific genetic mutation. Retevmo is specifically used in patients whose cancer has spread to other parts of the body (metastasized) or cannot be surgically removed. Non-Small Cell Lung Cancer Retevmo 80 mg capsule

Venclyxto (venetoclax) is a prescription medicine used to treat certain types of cancer, specifically chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is used in combination with other medicines such as rituximab or obinutuzumab for the treatment of adults with CLL or SLL who have received at least one prior therapy. Venclyxto is also used in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are 75 years old or older or who have other medical conditions that prevent the use of standard chemotherapy. Venetoclax works by blocking the action of a protein called BCL-2, which helps cancer cells survive and multiply. By blocking BCL-2, Venclyxto can help to kill cancer cells and slow down the progression of the disease. It is important to note that Venclyxto should only be used under the supervision of a qualified healthcare professional, as it can cause serious sid

Use of Enhertu ENHERTU is a prescription medication used to treat certain types of cancer. Specifically, it is used to treat HER2-positive breast cancer that has spread to other parts of the body and has not responded to other treatments. ENHERTU is a type of medication called an antibody-drug conjugate (ADC). ADCs are made up of an antibody that is designed to target a specific protein on cancer cells, and a chemotherapy drug that is attached to the antibody. Once the ADC attaches to the cancer cells, the chemotherapy drug is released and destroys the cancer cells. ENHERTU is given as an intravenous (IV) infusion over the course of 30 minutes. The dosage and frequency of the medication may vary depending on the patient's individual condition and response to treatment. It is important to note that ENHERTU may cause side effects, some of which can be serious. Common side effects may include nausea, vomiting, fatigue, hair loss, and decreased appetite. Patients should discuss

RADICAVA (EDARAVONE) Injection is a medication used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. As with any medication, RADICAVA may cause side effects in some people. It is important to understand the possible side effects of RADICAVA and to talk to your doctor if you experience any of these symptoms. Common side effects of RADICAVA may include: Bruising or swelling at the injection site Gait disturbance or difficulty walking Headache Skin rash or itching Fever These side effects are typically mild to moderate in severity and may go away on their own without treatment. However, if these side effects persist or worsen, it is important to talk to your doctor. Less common but more serious side effects of RADICAVA may include: Allergic reaction: In rare cases, RADICAVA may cause an allergic reaction, which can be life-threatening. Signs of an allergic reaction may include difficulty breathing, hives, or swelling of the face, lips, tongue, or thro